New algorithm could let kidney patients take less Anti-Rejection meds

NCT ID NCT06235892

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new tool called AGORA can safely identify kidney transplant patients who can take a lower dose of the anti-rejection drug tacrolimus. About 300 adults who are one year post-transplant and at low risk for rejection will be randomly assigned to either standard care or a reduced tacrolimus plan. The goal is to see if lowering the drug improves kidney function without causing rejection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORGAN GRAFTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORGAN GRAFTS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

CHU de NANTES
RECRUITING

Nantes, 44000, France

Contact
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, Spain

Contact
Oslo University Hospital
NOT_YET_RECRUITING

Oslo, Norway

Contact